Aoyang Pu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Aoyang Pu has a total of 36 co-authors. Here are the top co-authors by number of shared publications:
Huanhuan Sun
2 shared publications- Hyesoo Hwangbo
Department of Biomedical Sciences, City University of Hong Kong, Kowloon, China
2 shared publications - Kiwon Ban
Department of Biomedical Sciences, City University of Hong Kong, Hong Kong SAR, China
2 shared publications - Kwan Ting Chow
Department of Biomedical Sciences, City University of Hong Kong, Hong Kong 999077, China
2 shared publications Yimin Lai
2 shared publications- Bong-Woo Park
Department of Medical Life Science, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea
1 shared publication
Latest Publications
- Open Access
- 9 October 2026
- Published by Elsevier in SSRN Electronic Journal
Host-compatible cardiac fibroblast-derived ECM patches promote myocardial repair after infarction
Cardiac extracellular matrix (ECM) patches provide tissue-specific environments for localized cell delivery after myocardial infarction (MI), but their translation is limited by reliance on xenogeneic tissues or non-cardiac ECM sources. Here, we developed a scalable cardiac fibroblast (CF)-derived ECM patch that combines cardiac-associated matrix cues with improved host compatibility. A matrix-stimulatory cocktail and three-dimensional PLGA mesh culture system enhanced ECM production by multiple matrix-secreting cell types and enabled fabrication of transplantable patches. Transcriptomic and proteomic analyses demonstrated cardiac-associated signatures in human induced pluripotent stem cell-derived CFs and their ECM patches compared with non-cardiac fibroblast controls. In immunocompetent rats, same-strain rat CF-derived ECM patches induced less myocardial macrophage infiltration than xenogeneic human CF-derived patches. Mesenchymal stromal cell-loaded, same-strain CF-derived ECM patches produced sustained functional improvement, increased vascularization and viable myocardium, and reduced fibrosis after MI without systemic immunosuppression. These findings identify host compatibility as an important determinant of ECM patch-mediated cell therapy and establish CF-derived ECM as a promising platform for myocardial repair, with future potential for patient-derived and immune-matched applications.
- 9 October 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessHost-compatible cardiac fibroblast-derived ECM patches promote myocardial repair after infarction
Cardiac extracellular matrix (ECM) patches provide tissue-specific environments for localized cell delivery after myocardial infarction (MI), but their translation is limited by reliance on xenogeneic tissues or non-cardiac ECM sources. Here, we developed a scalable cardiac fibroblast (CF)-derived ECM patch that combines cardiac-associated matrix cues with improved host compatibility. A matrix-stimulatory cocktail and three-dimensional PLGA mesh culture system enhanced ECM production by multiple matrix-secreting cell types and enabled fabrication of transplantable patches. Transcriptomic and proteomic analyses demonstrated cardiac-associated signatures in human induced pluripotent stem cell-derived CFs and their ECM patches compared with non-cardiac fibroblast controls. In immunocompetent rats, same-strain rat CF-derived ECM patches induced less myocardial macrophage infiltration than xenogeneic human CF-derived patches. Mesenchymal stromal cell-loaded, same-strain CF-derived ECM patches produced sustained functional improvement, increased vascularization and viable myocardium, and reduced fibrosis after MI without systemic immunosuppression. These findings identify host compatibility as an important determinant of ECM patch-mediated cell therapy and establish CF-derived ECM as a promising platform for myocardial repair, with future potential for patient-derived and immune-matched applications.
- Open Access
- 19 May 2026
- Published by SAGE Publications in Journal of Tissue Engineering
- Vol. 17
Cell-free therapy for alopecia via the secretome of hiPSC-derived dermal papilla cells
Alopecia is highly prevalent and debilitating, yet current drugs provide limited, reversible benefit with notable side effects. We established a rapid protocol to generate human induced pluripotent stem cell–derived dermal papilla cells (hiPSC-DPCs) and demonstrated that their conditioned medium (CM) acts as a potent, cell-free hair-regenerative therapy. Transdermal delivery of hiPSC-DPCs or CM accelerated anagen re-entry and hair regrowth in depilated mice, and hiPSC-DPC CM outperformed minoxidil in promoting ex vivo hair-shaft elongation and in vitro proliferation and migration of primary DPCs and keratinocytes. Proteomic and metabolomic profiling revealed enrichment of growth factors, antioxidants, and immunomodulatory metabolites linked to TNF and PI3K–Akt signaling, conferring superior anti-inflammatory and cytoprotective properties relative to primary DPC CM. Moreover, hiPSC-DPC CM mitigated dihydrotestosterone (DHT)-induced pathology by suppressing androgen receptor expression and nuclear translocation. These findings position hiPSC-DPC secretome as a dual-functional, regenerative, and anti-androgenic biologic with translational potential for durable alopecia treatment.
- 19 May 2026
- Published by SAGE Publications in Journal of Tissue Engineering
- Vol. 17
Open AccessCell-free therapy for alopecia via the secretome of hiPSC-derived dermal papilla cells
Alopecia is highly prevalent and debilitating, yet current drugs provide limited, reversible benefit with notable side effects. We established a rapid protocol to generate human induced pluripotent stem cell–derived dermal papilla cells (hiPSC-DPCs) and demonstrated that their conditioned medium (CM) acts as a potent, cell-free hair-regenerative therapy. Transdermal delivery of hiPSC-DPCs or CM accelerated anagen re-entry and hair regrowth in depilated mice, and hiPSC-DPC CM outperformed minoxidil in promoting ex vivo hair-shaft elongation and in vitro proliferation and migration of primary DPCs and keratinocytes. Proteomic and metabolomic profiling revealed enrichment of growth factors, antioxidants, and immunomodulatory metabolites linked to TNF and PI3K–Akt signaling, conferring superior anti-inflammatory and cytoprotective properties relative to primary DPC CM. Moreover, hiPSC-DPC CM mitigated dihydrotestosterone (DHT)-induced pathology by suppressing androgen receptor expression and nuclear translocation. These findings position hiPSC-DPC secretome as a dual-functional, regenerative, and anti-androgenic biologic with translational potential for durable alopecia treatment.
- Open Access
- 31 January 2024
- Published by Royal Society of Chemistry (RSC) in Lab on a Chip
- Vol. 24 (6) , 1782-1793
On-chip droplet analysis and cell spheroid screening by capillary wrapping enabled shape-adaptive ferrofluid transporters
We propose a ferrofluid transporter for digital droplet manipulation in an additive-free and lossless manner. The transporter shows high reliability with an on-chip design for droplet-based bioanalysis and high throughput cell spheroid screening.
- 31 January 2024
- Published by Royal Society of Chemistry (RSC) in Lab on a Chip
- Vol. 24 (6) , 1782-1793
Open AccessOn-chip droplet analysis and cell spheroid screening by capillary wrapping enabled shape-adaptive ferrofluid transporters
We propose a ferrofluid transporter for digital droplet manipulation in an additive-free and lossless manner. The transporter shows high reliability with an on-chip design for droplet-based bioanalysis and high throughput cell spheroid screening.